Immunosuppressants Flashcards
Cyclosporine mech
Calcineurin inhibitor; binds cyclophilin. Blocks T cell activation by preventing IL-2 TRANSCRIPTION.
Cyclosporine use:
Transplant rejection, prophylaxis, psoriasis, rheumatoid arthritis
Cyclosporine Toxicity:
NEPHROTOXICITY, HTN, hyperlipidemia, hyperglycemia, tremor, hirsutism, gingival hyperplasia
Tacrolimus mech:
Calcineurin inhibitor; binds FK506 binding protein (FKBP). Blocks T cell activation by preventing IL-2 transcription.
Tacrolimus use:
Transplant rejection prophylaxis
Tacrolimus Toxicity:
Similar to cyclosporine, increased risk of diabetes and neurotoxicity; no ginigival hyperplasia or hirsutism.
Siroliums (Rapamycin) mech:
mTOR inhibitor; binds FKBP. Blocks T cell activation and B cell differentiation by preventing IL-2 signal transduction.
Sirolimus (Rapamycin) use:
Kidney transplant rejection prophylaxis
Sirolimus (Rapamycin) toxicity:
Anemia, thrombocytopenia, leukopenia, insulin resistance, hyperlipidemia; NON-NEPHROTOXIC.
Sirolimus notes:
Kidney ‘sir-vives’. synergistic with cyclosporine. Also used in drug-eluting stents.
Basiliximab mech:
monoclonal antibody; blocks IL-2R
Basiliximab use:
kidney transplant rejection prophylaxis.
Basiliximab toxicity:
Edema, HTN, tremor
Azathiprine mech
Antimetabolite precursor of 6-MP. Inhibits lymphocyte proliferation by blocking nucleotide synthesis.
Azathioprine clinical use:
Transplant rejection prophylaxis, rhematoid arthritis, Crohn disease, glomerolonephritis, other autoimmune conditions
Azathioprine toxicity:
Leukopenia, anemia, thrombocytopenia
Azathioprine additional notes:
6-MP degraded by xanthine oxidase; toxicity increased by allopurinol. pronounced ‘azathioPURINE’
Glucocorticoids mech
inhibit NF-kB. Suppress both B and T cell function by decreasing transcription of many cytokines.
Glucocorticoids use:
Transplant rejection prophylaxis (immune suppression), many autoimmune disorders, inflammation
Glucocorticoids toxicity:
Hyperglycemia, osteoporosis, central obestity, muscle breakdown, psychosis, acne, HTN, cataracts, peptic ulcers
Epoetin alfa (erythropoietin) use:
Anemias (especially renal failure
Thrombopoietin:
Thrombocytopenia
Oprelvekin (IL-11) use:
Thrombocytopenia
Filgrastim (granulocyte colony stimulating factor) use:
Recovery of bone marrow
Sargramostim (granulocyte-macrophage colony stimulating factor) use:
Recovery of bone marrow
Aldesleukin use:
IL-2; RCC, metastatic melanoma
IFN alpha:
Chronic Hep B and C, Kaposi Sarcoma, Kaposi Sarcoma, Hairy Cell Leukemia, Condyloma Acuminatum, RCC, malignant melanoma
IFN beta:
MS
IFN gamma
Chronic granulomatous disease
Therapeutic antibodies Are next
…..
Alemtuzumab
TARGET: CD52, Use: CLL, Notes: ‘ALYMtuzumab’ - chronic LYMphocytic leukemia
Bevacizumab
TARGET: VEGF. Use: Colorectal cancer, RCC
Cetuximab
Target: EGFR. USE: Stage IV colorectal cancer, head and neck cancer
Rituximab
Target CD20. USE: B-cell non-hodgkin lymphoma, rheumatoid arthritis (with MTX), ITP
Trastuzumab
Target: HER2/neu. USE: Breast cancer, gastric cancer. Notes: Tras2zumab
Autoimmune disease therapy:
infliximab, adalimuab, nataliziumab
INFLIXimab and aDALIMumab
Target: TNF-alpha. USE: IBD, rheumatoid arthritis, ankylosing spondylitis, psoriasis
Natalizumab
Target: alpha4-integrin (leukocyte adhesion). Use: MS, Crohn disease. RISK OF PML IN PATIENTS WITH JC VIRUS
Abciximab
Target: Glycoprotein IIb/IIIa. Clinical Use: anti-platelet agent for prevention of ischemic complications in patients undergoing percutaneous coronary intervention. NOTE: IIb times IIIa = abSIXimab
Denosumab
Target: RANKL. osteoporosis; inhibits osteoclast maturation (mimics OPG)
Digoxin immune Fab
Target: digoxin. Use: Antidote for digoxin toxicity
Omalizumab
Use: Allergic asthma; prevents IgE binding to FcERI
Palivizumab
Target: RSV F protein. USE: RSV prophylaxis for high risk infants. paliVIzumab for VIrus